Literature DB >> 15206060

The pharmacogenetics of antiretroviral therapy: a review of studies to date.

Erin Quirk1, Howard McLeod, William Powderly.   

Abstract

Although the ever-expanding armamentarium of antiretroviral drugs has significantly decreased the morbidity and mortality due to human immunodeficiency virus infection, patients and clinicians are increasingly faced with the problems of inadequate or toxic response to therapy that may be genetically mediated. Significant evidence now exists that interindividual differences, such as efficacy of therapy, hypersensitivity reactions, and metabolic complications as a result of antiretroviral therapy, are in part genetically determined. This article reviews the significant studies published to date in the area of the pharmacogenetics of antiretroviral therapy and summarizes current trends, as well as areas where further research is needed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15206060     DOI: 10.1086/421557

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  7 in total

1.  Can antiretroviral therapy be tailored to each human immunodeficiency virus-infected individual? Role of pharmacogenomics.

Authors:  Victor Asensi; Julio Collazos; Eulalia Valle-Garay
Journal:  World J Virol       Date:  2015-08-12

2.  Cardiovascular and Endothelial Disease in HIV Infection.

Authors:  Michelle S Cespedes; Judith A Aberg
Journal:  Curr Infect Dis Rep       Date:  2005-07       Impact factor: 3.725

Review 3.  Pharmacogenomics of CYP3A: considerations for HIV treatment.

Authors:  Sukhwinder S Lakhman; Qing Ma; Gene D Morse
Journal:  Pharmacogenomics       Date:  2009-08       Impact factor: 2.533

4.  Communication of pharmacogenetic research results to HIV-infected treated patients: standpoints of professionals and patients.

Authors:  Grégoire Moutel; Nathalie Duchange; François Raffi; Lama I Sharara; Ioannis Théodorou; Violaine Noël; Sandrine de Montgolfier; Ingrid Callies; François Bricaire; Christian Hervé; Catherine Leport
Journal:  Eur J Hum Genet       Date:  2005-09       Impact factor: 4.246

5.  Sociodemographic factors predict early discontinuation of HIV non-nucleoside reverse transcriptase inhibitors and protease inhibitors.

Authors:  Shaheena Asad; Todd Hulgan; Stephen P Raffanti; Jim Daugherty; Wayne Ray; Timothy R Sterling
Journal:  J Natl Med Assoc       Date:  2008-12       Impact factor: 1.798

Review 6.  Antiretroviral therapy : pharmacokinetic considerations in patients with renal or hepatic impairment.

Authors:  Sarah M McCabe; Qing Ma; Judianne C Slish; Linda M Catanzaro; Neha Sheth; Robert DiCenzo; Gene D Morse
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

7.  A comparative study of logistic regression based machine learning techniques for prediction of early virological suppression in antiretroviral initiating HIV patients.

Authors:  Kuteesa R Bisaso; Susan A Karungi; Agnes Kiragga; Jackson K Mukonzo; Barbara Castelnuovo
Journal:  BMC Med Inform Decis Mak       Date:  2018-09-04       Impact factor: 2.796

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.